Patent · US Active

Truncated von Willebrand Factor polypeptides for treating hemophilia

US11814421B2 · kind B2 · utility

0Cited by

9References

24Claims

0Family size

Assignee

CSL BEHRING LENGNAU AG · CH

Inventors

Stefan Schulte · Marburg, DE
Thomas Weimer · Gladenbach, DE
Sabine Pestel · Biberach, DE
Hubert Metzner · Marburg, DE
Steve Dower · Melbourne, AU

Key dates

Filing date	Nov 10, 2017
Grant date	Nov 14, 2023
Priority date	—
Expiry date	Dec 31, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.